Lessons learned fighting HIV can be applied to anti-cancer drug design

Cell Cycle

Volumn 5, Issue 5, 2006, Pages 463-464

  Gustchina, Alla ^a   Jaskólski, Mariusz ^b   Wlodawer, Alexander ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

Author keywords

Aids; Cancer; Drug design; HIV 1; HTLV 1; Leukemia; Protease

Indexed keywords

AMPRENAVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; INDINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR;

CRYSTALLOGRAPHY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAPAN; NUCLEAR MAGNETIC RESONANCE; PREVALENCE; SHORT SURVEY; T CELL LEUKEMIA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 33644764895     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.5.2490     Document Type: Short Survey

References (0)